Multiple dose studies of the effects of angiotensin converting enzyme inhibitors on renal function, urine output, and sodium excretion2-151
| Author/year | No patients | Drug dose (mg/day) | Duration (day) | Urinary Na output (mmol/day) | Creatinine clearance or GFR (ml/min) | Urine volume (ml/day) | MAP (mm Hg) |
| Saruta, 198327 | 6 | SQ14225 75 mg | 7 | 100 (5) to 165 (16) in 5 of 62-150 | Unchanged | 1400 (210) to 1800 (180)2-150 | 92.6 (7) to 87 (7) |
| Brunkorst, 198928 | 14 | Captopril 12.5 mg for 5 days then 25 mg for 5 days | 10 | 70 to 1252-150 | 53.7 (7.8) to 66.9 (15.1) | Fluid balance: +200 to –6002-150 | 84 (2.9) to 78.4 (2.9) |
| Ibarra, 199229 | 9 | Captopril 75 mg | 21 | 36.7 (9.5) to 103 (13.8) 7 of 9 patients2-150 | NA | NA | 86.9 (2.6) to 80.2 (3.7) |
| Van Vliet, 199230 | 8 | Captopril from 9 to 37.5 mg | 20 | 72.8 (35.2) to 1128.5 (63.5) in 4 responders2-150 | NA | 1207 (456) to 1646 (395) in 4 responders2-150 | 79.8 (7.3) to 72.6 (9) in 4 responders |
| 40.9 (35) to 42.4 (32) in 4 non-responders | 1107 (334) to 1375 (424) in 4 non-responders | 86.3 (5.9) to 84.2 (9.4) in 4 non-responders | |||||
| Wood, 198531 | 4 | Captopril from 18.75 to 37.5 mg | 3 | 14.25 to 6.52-152 | 70 to 462-152 | NA | 87 to 782-152 |
| Tsai, 199632 | 25 | Captopril 6.25 tds | 14 | 20 (5) to 26 (6) | 45 (11) to 40 (10) | 790 (111) to 725 (85) | 88 (3) to 86 (4) |
| 25 | Placebo | 14 | 21 (6) to 18 (4) | 41 (10) to 38 (11) | 653 (78) to 750 (97) | 86 (2) to 85 (3) | |
| Ohnishi, 199433 | 10 | Enalapril 10 mg | 8 | 73 to 1102-152 2-150 | 47 to 602-152 2-150 | 1800 to 23002-152 2-150 | NA |
| Amarapurkar, 199434 | 8 | Enalapril 10 mg | 7 | NA | 46.5 (15.4) to 73.2 (19.7)2-150 | NA | NA |